Anthony W. Tolcher
Texas Oncology(US)Nektar Therapeutics (United States)(US)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research, Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology
Most-Cited Works
- → Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles(2010)2,475 cited
- → Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies(2001)998 cited
- → Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors(2015)774 cited
- → Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors(2016)742 cited
- → First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors(2011)541 cited
- → Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma(1997)